1. Home
  2. BLIV vs ATRA Comparison

BLIV vs ATRA Comparison

Compare BLIV & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLIV
  • ATRA
  • Stock Information
  • Founded
  • BLIV 2014
  • ATRA 2012
  • Country
  • BLIV Singapore
  • ATRA United States
  • Employees
  • BLIV N/A
  • ATRA N/A
  • Industry
  • BLIV
  • ATRA Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • BLIV
  • ATRA Health Care
  • Exchange
  • BLIV NYSE
  • ATRA Nasdaq
  • Market Cap
  • BLIV 39.8M
  • ATRA 40.1M
  • IPO Year
  • BLIV 2025
  • ATRA 2014
  • Fundamental
  • Price
  • BLIV $4.33
  • ATRA $7.80
  • Analyst Decision
  • BLIV
  • ATRA Buy
  • Analyst Count
  • BLIV 0
  • ATRA 5
  • Target Price
  • BLIV N/A
  • ATRA $17.75
  • AVG Volume (30 Days)
  • BLIV 154.8K
  • ATRA 78.0K
  • Earning Date
  • BLIV 01-01-0001
  • ATRA 05-15-2025
  • Dividend Yield
  • BLIV N/A
  • ATRA N/A
  • EPS Growth
  • BLIV N/A
  • ATRA N/A
  • EPS
  • BLIV N/A
  • ATRA N/A
  • Revenue
  • BLIV $1,355,200.00
  • ATRA $199,732,000.00
  • Revenue This Year
  • BLIV N/A
  • ATRA N/A
  • Revenue Next Year
  • BLIV N/A
  • ATRA N/A
  • P/E Ratio
  • BLIV N/A
  • ATRA N/A
  • Revenue Growth
  • BLIV N/A
  • ATRA 475.53
  • 52 Week Low
  • BLIV $2.69
  • ATRA $5.01
  • 52 Week High
  • BLIV $6.40
  • ATRA $18.71
  • Technical
  • Relative Strength Index (RSI)
  • BLIV N/A
  • ATRA 58.85
  • Support Level
  • BLIV N/A
  • ATRA $6.80
  • Resistance Level
  • BLIV N/A
  • ATRA $8.10
  • Average True Range (ATR)
  • BLIV 0.00
  • ATRA 0.59
  • MACD
  • BLIV 0.00
  • ATRA 0.07
  • Stochastic Oscillator
  • BLIV 0.00
  • ATRA 82.46

About ATRA Atara Biotherapeutics Inc.

Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).

Share on Social Networks: